Company / Free Cash Flow
Caribou Biosciences, Inc. Free Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$112.4M
FY2025
5-year range
-$112.4M / -$32.9M
FY2021-FY2025
Trend
-7.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has declined for 4 consecutive years, from -$33M in FY2021 to -$112M in FY2025.
Based on SEC 10-K filings.
-$112M in FY2025.
Declined from -$97M to -$112M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Caribou Biosciences, Inc.'s free cash flow has declined for 4 consecutive years.
- In FY2025, free cash flow decreased 7.1% year-over-year.
- Peak free cash flow was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$112.4M | -7.1% |
| FY2024 | -$104.9M | -7.7% |
| FY2023 | -$97.4M | -181.2% |
| FY2022 | -$34.6M | -5.3% |
| FY2021 | -$32.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026